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ACRONYMS AND ABBREVIATIONS 
 
 
 
 
 
APD action potential duration 
AV atrioventricular 
BG bigeminy 
EAD early afterdepolarization 
DAD delayed afterdepolarization 
DMSO dimethyl sulfoxide 
ECG electrocardiogram 
ICaL inward L-type calcium current 
IK delayed rectifier potassium current 
IKr the rapid component of the delayed rectifier potassium current  
IK1 inward rectifier potassium current 
INa inward sodium current 
LQTS long QT syndrome 
LTV long-term variability 
NCX Na+/Ca2+ exchanger 
QTc heart rate corrected QT interval 
SCD sudden cardiac death 
STV short-term variability 
TdP Torsades de Pointes 
TDR transmural dispersion of repolarization  
TWLI T-wave lability index 
VF ventricular fibrillation 
VPB ventricular premature beat 
VT ventricular tachycardia 
vs versus 
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1 INTRODUCTION 
1.1 Background of the study 
The cardiovascular diseases accounted for more deaths than any other single cause of 
death in the United States since 19001. More than 450,000 sudden cardiac death (SCDs) event 
occurs in the United States annually2. Pharmaceutical companies are really interested in the 
development of great number of antiarrhythmic drugs, since tachyarrhythmias are the most 
frequent causes of SCD. However, some clinical trials, such as CAST3 and SWORD4 found 
evidence that both Vaughan-Williams Class IC Na+-current (INa) blockers and Class III. rapid 
delayed-rectifier K+-current (IKr) blockers induce significant arrhythmia risk-enhancement, so 
called “proarrhythmia”, which is defined as the production of de novo arrhythmias or 
aggravation of existing arrhythmias. 
Dessertenne was the first who recognized a specific ECG pattern with twisting points 
and rotating peaks, described as “Torsades de Pointes” (TdP), which often associated with 
proarrhythmia by drugs that cause QT-prolongation5. TdP is considered a life-threatening 
form of polymorphic ventricular tachycardia, which can be evoked by several cardiac or non-
cardiac drugs that disturb the process of repolarization of the myocytes. TdP has a 
characteristic pathophysiology (Figure 1, discussed in detail below) and can manifest as 
acutely decreased pump function and haemodynamic instability, leading to syncope 
(sometimes with seizure-like activity), or via transformation to ventricular fibrillation, causing 
SCD. 
 
 
Figure 1 A representative recording of a TdP from an anaesthetized rabbit experiment 
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1.2 Development of Torsades de Pointes 
According to the most widely accepted theory, the mechanism of TdP initiation 
(trigger) involves an early (EAD) or delayed (DAD) afterdepolarization-induced ectopic beat, 
while the mechanism of the arrhythmia maintenance (substrate) involves re-entry circuits 
produced by an increase in spatial dispersion of the repolarization of the ventricular wall6. 
The TdP-maintaining mechanism includes the ‘4 dimensions’ of dispersion of cardiac 
repolarization in space and time: (1) transmural dispersion of repolarization (TDR); (2) apico-
basal dispersion; (3) interventricular dispersion; and (4) temporal dispersion. Temporal 
dispersion includes instability that can be a consequence of the above-mentioned initiating 
mechanisms7. For example, dofetilide, an inhibitor of the rapid component of the delayed 
rectifier potassium current (IKr), prolongs repolarization, induces EAD, increases dispersion of 
repolarization and can evoke TdP8. Numerous cardiac and non-cardiac drugs have been 
withdrawn from the clinical use or relabeled due to their documented proarrhythmic 
potential9. The development of TdP depends on several factors. Serum electrolyte levels, 
disturbance in autonoumos nervous system, cardiac functional and structural diseases, the 
cooperation of potassium channels during repolarization etc7. 
1.3 Biomarkers in prediction of Torsades de Pointes 
As the overall incidence of TdP is very low10, 11, there is a great need to find highly 
sensitive and specific surrogate biomarkers of TdP. Several surrogate biomarkers were 
proposed recently. An index of ventricular transmural dispersion of repolarization, the 
interval between the peak and the end of T wave (Tpeak-Tend) has been suggested, which 
may have prognostic value for proarrhythmic risk12. Beat-to-beat non- alternating T-wave 
lability, which was measured by the T wave lability index (TWLI) occurred in patients with 
inherited LQTS was associated with a history of prior cardiac events13. Hondeghem et al. 
established a proarrhythmia screening system (SCREENIT), which assess the triangulation, 
reverse use dependence, instability and dispersion (TRIaD) as predictors of drug-related 
proarrhythmia14. Since, spatial and temporal inhomogeneity of repolarization, annotated “4 
dimensions of dispersion”7, have a crucial role in the development of TdP, parameters that 
quantify dispersion15-18 have been reported to have better predictive value for TdP 
development. 
However, the above mentioned parameters have not been fully confirmed. To date, 
among many suggested biomarkers, still the ECG QT and heart rate corrected QT (QTc) 
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intervals are the most accepted and the most frequently-used TdP surrogates7, 19, 20. However, 
the predictive power of these parameters has been questioned8, 21, 22. 
Recently, Thomsen et al. have proposed beat-to-variability of the QT intervals as a 
parameter of temporal inhomogeneity of repolarization, which may determine the 
proarrhythmic outcome in a dog in vivo proarrhythmia model23. It has been shown that beat-
to-beat variability of the repolarization measured in regular rhythm predicted TdP in clinical24 
and experimental16, 25, 26 settings. However, beat-to-beat variability of repolarization measured 
in regular rhythm did not predict drug-induced TdP in anaesthetized rabbits27-30 and guinea 
pigs31. One of the possible reasons is that TdP is almost always preceded by simple, drug-
induced arrhythmias which do not allow the measurement of the beat-to-beat variability of 
repolarization in sinus or regular rhythm. These ‘preceding’ arrhythmias can occur well 
before temporal instability of repolarization could be detected. In order to overcome this 
problem, we developed a method to allow ECG intervals to be measured during disorganized 
non-sinus rhythm before TdP occurrence28, 32. This allowed established beat-to-beat 
variability parameters to be derived irrespective of rhythm28. To differentiate from published 
beat-to-beat variability parameters described by others, all of which are derived during stable 
rhythm (sinus beat-to-beat variability parameters), we coined the term absolute to describe the 
derived beat-to-beat variability parameters of the ECG intervals28. Absolute beat-to-beat 
variability parameters of the ECG intervals accurately predicted drug-induced TdP28 and also 
the development of ischaemic VF33, whereas equivalent variables measured in sinus rhythm 
failed to predict TdP and VF liability27, 28. 
1.4 Preclinical proarrhythmia assays 
Most pharmaceutical companies conduct cardiovascular safety studies before selection 
of candidate drugs for development. Table 1. summarizes the available preclinical models for 
TdP risk assessment7. Since the in vitro, isolated, rabbit heart model is one of the most 
frequently used preclinical model for testing the proarrhythmic liability of drugs, 
relatively simple and does not require high amount of drug, we chose this model for 
our studies (see the paragraph 1.5 and 1.6) 
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Preclinical proarrhythmia assays 
In vitro assays 
1. Human Ether-a -`Go-Go (hERG) subunit assay (isolated cardiac 
ventricular myocytes or cell lines expressing hERG) 
2. Purkinje fibre and papillary muscle action potential duration assays 
3. Arterially perfused wedge preparations 
4. Langendorff heart (SCREENIT) 
 
In vivo assays in normal animals 
1. 1-adrenoceptor-sensitized anaesthetized rabbit model 
2. Conscious ECG telemetry in dogs and monkeys 
3. Slow delayed-rectifier potassium current-inhibited 
4. Anaesthetized rabbit and canine models 
 
Pathological in vivo TdP models 
1. Chronic atrioventricular-block animal models 
2. Failing rabbit heart model 
 
Table 1. Preclinical proarrhythmia based on the classification of the review of Farkas&Nattel7 
1.5 The in vitro, isolated, AV ablated rabbit heart model  
The in vitro, isolated, AV ablated rabbit heart model is frequently used for testing the 
proarrhythmic liability of drugs34. The primary objective of this study was to investigate the 
role of Na+/Ca2+ exchanger (NCX) in the development of TdP in AV ablated isolated rabbit 
hearts. Interestingly, the specific NCX blocker (SEA0400) could not decrease the incidence of 
TdP in this model questioning the pivotal role of NCX in the formation of TdP. As the ability 
of other pharmacological interventions to reduce the incidence of TdP induced by K+ channel 
blocking drugs has not been fully examined in this model, a second series of experiments was 
conducted to validate the model with drugs known to alleviate TdP in other experimental 
models. Thus, the anti-arrhythmic effect of the inhibition of the L-type Ca2+ current (ICaL) by 
verapamil and the inhibition of the INa by lidocaine was tested against dofetilide-induced TdP 
in isolated, Langendorff-perfused, AV-ablated rabbit hearts. Also, an attempt was made to 
determine whether the occurrence of dofetilide-induced TdP was related to the prolongation 
of the rate corrected QT (QTc) interval or the beat-to-beat variability of the QT interval in the 
applied model. 
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1.6 The in vitro, isolated, reduced repolarization reserve rabbit heart model 
According to the theory of repolarization reserve, there is some redundancy in 
repolarizing currents in the myocardium. Inhibition of a single repolarizing current can still 
allow sufficient repolarization via other repolarizing currents. However, concomitant 
inhibition of two or more repolarizing ion channels reduces repolarization reserve and 
potentiates inhibition of cardiac repolarization, which can result in TdP development35-37. In 
human and also in many mammals applied for laboratory experiments (e.g. guinea pig, rabbit, 
dog) the main outward repolarizing current is the rapid component of the IKr, that is a 
common target of drugs with proarrhythmic side effects38. However, under normal conditions, 
IKr block just rarely evokes serious arrhythmias (e.g. TdP) because another repolarizing 
current, e.g. the slow component of the delayed rectifier K+ current (IKs), becomes more 
prominent and compensates the repolarization lengthening and decreases the arrhythmogenic 
effect of the IKr blocker39-42. However, the concomitant block of IKr and IKs currents 
constitutes an increased risk to TdP development25, 30, 41-45. 
The aim of this study was to investigate which TdP biomarker (QTc, sinus or absolute 
beat-to-beat variability of the QT interval) can adequately indicate the increased risk of 
proarrhythmia in the setting of reduced repolarization reserve in an in vitro, spontaneous 
beating rabbit heart proarrhythmia model. Reduced repolarization reserve was achieved by 
concomitant pharmacological inhibition of IKr and IKs. 
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2 MATERIALS AND METHODS  
2.1 Animals in the study 
Female New Zealand white rabbits weighing 2.5±0.24 kg were used for the 
experiments. Animals were obtained from WOBE Ltd. (Budapest, Hungary) and acclimatized 
at the site for at least 3 to 4 days before any experiments started. Animals were kept under 
standard conditions (temperature 21°C; relative humidity 55–65%; 12:12 h dark/light cycle) 
on commercial laboratory chow and tap water ad libitum. Animal maintenance and research 
were conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and the Local Ethical Committee of Gedeon Richter Plc. (RG-
MÁB No. 44/2001). 
2.2 Langendorff perfusion of isolated rabbit hearts 
The animals were anticoagulated with sodium heparin (1000 International Units) 
injected into the marginal ear vein and stunned by a blow to the neck. The heart was rapidly 
removed via thoracotomy and rinsed in ice-cold modified Krebs–Henseleit buffer solution 
containing (in mM): NaCl 118.5, CaCl2 1.8, glucose 11.1, MgSO4 0.5, NaH2PO4 1.2, 
NaHCO3 25, and KCl 3. A K+ concentration of 3  mM was chosen, as the proarrhythmic 
action of dofetilide tended to be exacerbated by perfusion with 3  mM K+ versus (vs) 4  mM 
K+ in isolated, AV-blocked rabbit hearts46. The aorta was cannulated and hung on a 
Langendorff apparatus and hearts were retrogradely perfused at a constant temperature of 
37°C with the modified Krebs–Henseleit buffer solution described above. A mixture of 95 % 
O2 and 5 % CO2 was bubbled through the buffer, which was equilibrated to pH 7.4. All 
solutions were filtered (5 m pore size filter) before use. The perfusion pressure was 
maintained constant at 80 mmHg. Volume conducted electrocardiogram (ECG) was recorded 
by using National Instruments data acquisition hardware (PC card, National Instruments, 
Austin, TX, USA) and SPEL Advanced Haemosys software (version 2.76, Experimetria Ltd. 
and Logirex Software Laboratory, Budapest, Hungary). Coronary flow was measured with a 
glass flowmeter (Cole-Parmer Instrument Company, Vernon Hills, Illinois, USA) positioned 
immediately above the retrogradely perfused aorta and was later corrected for the weight of 
each heart to give values in ml min 1 g-1. 
In AV ablated rabbit hearts an incision was made in the right atrium and the AV node 
was ablated using forceps two minutes after mounting the heart. AV ablation was regarded 
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successful when the P wave was dissociated from the QRS complex on real-time ECG 
recording. After AV ablation the hearts were allowed to beat in their own spontaneous 
rhythm. Since a single ventricular pacing stimulus can initiate TdP in the presence of a Class 
III antiarrhythmic drug (e.g. E-4031) in isolated, AV-blocked rabbit hearts47, ventricular 
pacing was not applied in the present experiments in order to avoid the occurrence of 
electrical pacing induced arrhythmias. Hearts were allowed 15 min to equilibrate before 
starting the experimental protocol. At the end of each experiment, the atria were removed 
from the heart and the ventricles were weighed. 
2.3 The in vitro, isolated, AV ablated rabbit heart model  
2.3.1 Experimental protocol in isolated AV ablated rabbit heart study 
The experiments were design to examine whether it is possible to reduce dofetilide-
induced TdP with other drugs in the applied model. Lidocaine and verapamil were chosen as 
test drugs as they could successfully reduce the incidence of drug-induced TdP in other 
experimental models48, 49. The experiments comprised three groups of hearts: 1.) 100 nM 
dofetilide (DOF), 2.) 30 M lidocaine+100 nM dofetilide (LID+DOF), 3.) 750 nM 
verapamil+100 nM dofetilide (VER+DOF). Each group contained n=8 hearts. The 
administration of lidocaine or verapamil or the solvent DMSO was started at the beginning of 
the ‘pretreatment’ period, whereas dofetilide was added to the perfusion solution at the 
beginning of the ‘treatment’ period (Table 2). 
 
 Group  n  Pretreatment (20 min) Treatment (30 min)  
 
 
  
Dofetilide 100 nM 8 DMSO DMSO+dofetilide 
Lidocaine 30 µM+Dofetilide 100 nM 8 DMSO+lidocaine DMSO+lidocaine+dofetilide 
Verapamil 750 nM+Dofetilide 100 nM 8 DMSO+verapamil DMSO+verapamil+dofetilide 
 
 
  
 
Table 2. The experimental protocol applied in isolated, Langendorff-perfused, AV-blocked rabbit hearts. The groups of 
hearts, the periods of the experiments and the applied drugs are summarized. In the baseline period of the experiments, all 
hearts were perfused with Krebs buffer (not signed); the perfusion solution was then switched to the test drug in the 
experiments (pretreatment); in the last period dofetilide was added to the perfusion (treatment). Group size is indicated by n. 
2.3.2 ECG analysis and coronary flow measurement in AV ablated rabbit heart study 
ECG intervals and coronary flow were measured at predetermined time points. After 
completion of the experiments, the data were replayed and the QT and RR intervals were 
measured by manual positioning of on-screen markers. The QT interval was defined as the 
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time between the first deviation from the isoelectric line of QRS complex until the end of the 
TU wave. In the rabbit hearts, where the T or U wave overlapped the following QRS complex 
of the subsequent ventricular beat, the extrapolation method was used to measure the length 
of the QT (or QU) interval50. 
As QT interval is influenced by the heart rate, baseline data for ventricular heart rates 
and QT intervals were used to determine the relationship between the RR interval and the QT 
interval in sinus rhythm before AV ablation and in idioventricular escape rhythm after AV 
ablation according to Batey et al.51 and Farkas et al.52. These data were obtained from 56 
isolated, Langendorff-perfused rabbit hearts. Forty consecutive QT intervals were measured 
together with the corresponding RR intervals in each hearts immediately before and 10 min 
after the mechanical AV ablation. Simple linear regression revealed a positive correlation 
between QT and RR intervals in sinus rhythm (QTSinus=0.326RR + 103.4) as well as in 
idioventricular escape rhythm (QTAV-block=0.081RR + 186.8), though the regression 
coefficient (R) and the slope of the regression line were greater during sinus rhythm as 
compared with the values calculated in idioventricular escape rhythm (Figures 2a and 2b). As 
there was a difference between the slope of the regression line of the sinus and the 
idioventricular rhythm, a QT correction was calculated for either rhythm in a manner similar 
to that described by Batey et al.53. The equations were rearranged to allow the calculation of 
the rate-corrected QT interval in sinus rhythm (QTc-Sinus) at an RR interval of 300 ms (i.e. a 
ventricular rate of 200 beats min-1) using the formula QTc-Sinus=QTSinus - 0.326(RR-300) and 
in idioventricular escape rhythm (QTc-AV) at an RR interval of 500 ms (i.e. a ventricular rate 
of 120 beats min-1) using the formula QTc-AV=QTAV-block - 0.081(RR-500). With these 
equations, plotting QTc-Sinus and QTc-AV against the corresponding RR interval produces a 
regression line with a slope of zero (Figure 2c and 2d) indicating that these corrections 
remove the influence of heart rate. As we examined drug effects after AV ablation in 
idioventricular escape rhythm, all QTc intervals in this study were corrected according to the 
QTc-AV. 
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Figure 2. Correlation between individual values of the QT and RR intervals in sinus rhythm (A) and after AV ablation (B) in 
isolated Langendorff-perfused rabbit hearts. Correlation between individual values of the ‘rate-corrected’ QT intervals and 
the RR intervals in sinus rhythm (C) and after AV ablation (D) in isolated Langendorff-perfused rabbit hearts. QTc-Sinus, the 
heart rate-corrected QT interval during sinus rhythm; QTc-AV, the ventricular heart rate-corrected QT interval after AV 
nodal ablation. AV, atrioventricular; QTc, heart rate-corrected QT interval. 
 
Coronary flow values were read directly from the flowmeter every 5 min during the 
experiment and 1 min before and after switching to a different perfusion solution and 
normalized to heart weight. 
2.3.3 Measurement of the absolute variability of the QT intervals and the RR intervals 
The absolute variability of the QT and the RR intervals was determined from the 
manual measurement data on 40 consecutive QT intervals and the corresponding RR intervals 
at predetermined time points, i.e. in the last min before AV ablation, in the last min of drug-
free state after AV ablation, in the last min of the ‘pretreatment’ period before switching to 
the dofetilide perfusion, and in the 5th min of the dofetilide infusion or before the onset of 
TdP. A computer program was developed in a .NET environment to obtain the following 
parameters of the absolute variability of the QT and RR intervals: For a sequence of RR or 
QT interval durations, the ‘root mean square’ (RMS) was calculated according to the 
following definition: where represents the sequence of RR or QT interval durations and is the 
total number of intervals. Another approach for characterizing the absolute variability of RR 
and QT intervals is to take their successive differences (where represents the RR or QT 
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interval durations and is the total number of intervals) and calculate the root mean square of 
these differences: where denotes the mean value. The percentage of successive QT intervals 
that differ by more than 8 ms (PNN8), the ‘instability’ of the RR and QT intervals, the ‘short-
term variability’ (STV) and the ‘long-term variability’ (LTV) of the RR and QT intervals 
were calculated as described earlier27. 
2.3.4 Exclusion criteria in AV ablated rabbit heart study 
Any heart with a coronary flow < 3 ml min-1g-1 or asystole longer than 20 s during the 
whole experimental protocol was excluded. Longer than 20 s asystole was found after the 
start of dofetilide perfusion in 6 hearts pre-treated with verapamil and in 3 hearts pre-treated 
with lidocaine, these hearts were excluded. All excluded hearts were replaced to maintain 
equal group sizes. 
2.4 The in vitro, isolated, reduced repolarization reserve rabbit heart model 
2.4.1 Experimental protocol in isolated, reduced repolarization reserve rabbit heart study 
In the first set of experiments three groups of hearts were compared: 1) control group of 
hearts perfused with dimethyl sulphoxide (DMSO), that is the solvent of dofetilide and HMR-
1556 (‘Control A’ group; n=6); 2) hearts perfused with dofetilide at 15 nM (‘Dof 15’ group; 
n=8); 3) hearts perfused with HMR-1556 at 460 nM + dofetilide at 15 nM (‘HMR + Dof 15’ 
group; n=6)(Table 3). 
In the first set of experiments there were only few drug-induced arrhythmias, therefore 
we performed a second set of experiments, in which we intended to increase the incidence of 
arrhythmias. In the second set of experiments four groups (each contained 8 hearts) were 
compared: 1) control group of hearts perfused with DMSO and water, the latter is the solvent 
of catecholamines (‘Control B’ group); 2) hearts perfused with catecholamines (epinephrine 
25 nM + norepinephrine 100 nM) + DMSO (‘Cat Control’ group); 3) hearts perfused with 
catecholamines + dofetilide at 50 nM (‘Cat + Dof 50’ group); 4) hearts perfused with 
catecholamines + HMR-1556 at 460 nM + dofetilide at 50 nM (‘Cat + HMR + Dof 50’ 
group)(see Table 4). 
The administration of the IKs inhibitor HMR-1556 or its solvent (DMSO) was started at 
the beginning of a 30 min pretreatment period. Dofetilide or its solvent (DMSO) was added to 
the perfusion solution after the pretreatment period, at the beginning of a 30 min treatment 
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period. In the second set of experiments catecholamines or their solvent were administered 
from the beginning of the pretreatment period (Tables 3 and 4). 
PERIOD 
GROUP 
Pretreatment 
(30 min) 
Treatment 
(30 min) 
Control A (n=6) vehicle vehicle 
Dof 15 (n=8) vehicle Dofetilide 15 nM 
HMR + Dof 15 (n=6) HMR HMR + Dofetilide 15 nM 
 
Table 3. Experimental protocol in the first set of experiments. ‘Dof 15’: group perfused with 15 nM dofetilide; ‘HMR + 
Dof 15’: group perfused with 460 nM HMR-1556 and 15 nM dofetilide. HMR: HMR-1556 at 460 nM, vehicle: DMSO 
(dimethyl sulphoxide), the common solvent of the dofetilide and HMR-1556 
 
PERIOD 
GROUP 
Pretreatment 
(30 min) 
Treatment 
(30 min) 
Control B (n=8) vehicles vehicles 
Cat control (n=8) Cat. + vehicle Cat. + vehicle 
Cat + Dof 50 (n=8) Cat. + vehicle Cat. + Dofetilide 50 nM 
Cat + HMR + Dof 50 (n=8) Cat. + HMR Cat. + HMR + Dofetilide 50 nM 
 
Table 4. Experimental protocol in the second set of experiments. ‘Cat + Dof 50’: group perfused with catecholamines and 
50 nM dofetilide; ‘Cat + HMR + Dof 50’: group perfused with catecholamines, 460 nM HMR-1556 and 50 nM dofetilide. 
Cat.: catecholamines (epinephrine 25 nM + norepinephrine 100 nM). Vehicles in the ‘Control B’ group are water acidified 
with ascorbic acid (the solvent of the catecholamines) and DMSO (the common solvent of the dofetilide and HMR-1556). 
Vehicle in the other groups is only DMSO. For further details see Table 3. 
 
In the first set of experiments we aimed to achieve a sufficient impairment of the 
repolarization without provoking a prominent arrhythmic activity. Thus, the selective IKr 
blocker dofetilide was applied at a concentration of 15 nM, which inhibited approximately 
50% of the IKr K+ current54, 55 and led to QTc prolongation without significant arrhythmic 
activity in our pilot study. 
In the second set of experiments we intended to increase the incidence of arrhythmias 
by further repolarization impairment. The concentration of dofetilide was increased to 50 nM 
in order to achieve complete inhibition of IKr. Since IKs blockade does not significantly 
increased repolarization instability unless -adrenergic stimulation is added in canines in 
vivo56-58, catecholamines were added to the perfusion solution to mimic the sympathetic 
activity and to boost the function of IKs (and the effect of IKs inhibition) in the isolated rabbit 
hearts. 
Since the IKs inhibitor HMR-1556 may adsorbs to glass or plastic surfaces, leading to 
reduced effective drug concentrations in the heart, the concentration of HMR-1556 was 
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measured in the perfusate right above the heart by the means of spectrophotometry (Hitachi F-
4000, Hitachi Ltd. Tokyo, Japan) with an excitation and emission wavelength of 295 nm and 
325 nm, respectively (data not shown). Since the IC50 of HMR-1556 ranged between 
10.5 nM59 and 65 nM44, our target concentration of HMR-1556 was 250 nM in order to 
achieve a significant inhibition of the IKs. However, it was found in the pilot experiments that 
the concentration of HMR-1556 in the perfusate was lower at the level of the aorta than in the 
working buffer. Thus, we increased the concentration of HMR-1556 to 460 nM in the 
working buffer, which resulted in a stable concentration of ~250 nM HMR-1556 in the 
perfusate at the level of the hearts in our perfusion setup. 
2.4.2 Measurement of the ECG intervals and QTc in, reduced repolarization reserve rabbit 
heart study 
ECG intervals were measured in sinus rhythm at predetermined time points (14, 25, 
35, 44, 50, 55 min). After the completion of experiments, the data were replayed with the 
SPEL Advanced Haemosys software (version 2.76, Experimetria Ltd. and Logirex Software 
Laboratory, Budapest, Hungary). The software averaged the ECG signal from 20 consecutive 
sinus beats at the predetermined time-point. If there were not 20 consecutive sinus beats at the 
predetermined time point or in the preceding or subsequent 30 sec, then the measurement was 
not performed at the time point. The RR and QT intervals were measured by manual 
positioning on screen markers in the signal averaged ECG. Heart rate was calculated from the 
RR interval. 
The QT interval is influenced by the heart rate, thus rate corrected QT interval (QTc) 
was calculated with a correction method described earlier51, 60. Baseline data in sinus rhythm 
for QT intervals together with the corresponding RR intervals were obtained from pooled data 
of our laboratory (from 100 isolated, Langendorff-perfused rabbit hearts prepared as 
described above). The linear regression between QT and RR intervals was: QT = 0.3381RR + 
89.85. This equation was rearranged to allow the calculation of the rate-corrected QT interval 
at a mean RR interval of 340 ms (i.e. a ventricular rate of ~177 beats min-1) using the formula 
QTc = QT - 0.3381(RR-340). With these equations, plotting QTc against the corresponding 
RR interval produces a regression line with a slope of zero (data not shown), indicating that 
these corrections successfully removed the influence of heart rate. 
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2.4.3 Measurement of the absolute and sinus beat-to-beat variability of the QT and RR 
interval in reduced repolarization reserve rabbit heart study 
To determine beat-to-beat variability of the RR and QT intervals, all analyses were 
based on samples of 40 consecutive ventricular complexes (RR intervals) at the 
predetermined time points, that is at baseline (1 min before the pretreatment period), in the 
last min of the pretreatment period and in the 5th min of the treatment period. From these 
samples, each of the 40 RR and QT intervals were measured manually, then the short-term 
variability (STV) and the long-term variability (LTV) of the RR and QT intervals were 
derived as described earlier15, 16, 27, 32, 61. 
The derived beat-to-beat variability parameters described above are referred to 
absolute beat-to-beat variability parameters when the raw ECG interval data were taken 
irrespective of the rhythm i.e., regardless of whether rhythm was sinus or non-sinus at the 
time-point of the measurement. The derived beat-to-beat variability parameters described 
above are referred to sinus beat-to-beat variability parameters when the raw ECG interval data 
were taken from samples of 40 consecutive complexes strictly in sinus rhythm at the 
predetermined time-point. The sample of 40 consecutive sinus complexes was measured only 
if it was preceded by at least 10 arrhythmia-free beats in order to avoid any effect of 
preceding arrhythmias on the ECG intervals. 
In the first set of experiments arrhythmias were infrequent, therefore the measurement 
of the ECG intervals could be done in stable sinus rhythm at all of the predetermined time 
points. Thus, only sinus beat-to-beat variability parameters were determined. However, in the 
second set of experiments, hearts usually experienced arrhythmias during drug perfusion at 
the predetermined time points. Thus, the measurement of the ECG intervals in sinus rhythm 
must have been done before the predetermined time point; if there were not 50 consecutive 
sinus beats at the predetermined time point or in the preceding 2 min, then the measurement 
was not performed and sinus beat-to-beat variability parameters were not determined at the 
time point. 
2.4.4 Arrhythmia diagnosis in reduced repolarization reserve rabbit heart study 
The incidence and the time to onset of arrhythmias were determined. Ventricular 
premature beat, bigeminy, salvo and ventricular fibrillation were defined according to the 
Lambeth Conventions62. TdP was defined as a polymorphic ventricular tachycardia consisting 
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of four or more ventricular complexes where clear twisting of the QRS complexes around the 
isoelectric axis could be seen in at least one ECG lead32. Runs of 4 or more ventricular 
premature beats without the TdP-like twisting QRS morphology were differentiated from TdP 
and were defined as ventricular tachycardia. Blocks in the conduction system were also 
monitored. Conduction disturbances included atrioventricular (AV) blocks and 
intraventricular conduction defects (right or left bundle branch blocks)28. 
2.4.5 Exclusion criteria in reduced repolarization reserve rabbit heart study 
Any heart with a sinus rate < 120/min or a coronary flow > 10 ml/min/g or < 3 ml/min/g 
5 min before the start of the 60 min drug perfusion protocol, or not in a constant sinus rhythm 
before the start of the 60 min drug perfusion, was excluded. In the first set of experiments, 
excluded experiments were not replaced as they may not have influenced the main results. In 
the second set of experiments all excluded hearts were replaced to maintain equal group sizes. 
2.5 Study designs  
The choice of drug solution was made by reference to a randomization table in each in 
vitro study. Randomization was achieved by coding each group with a letter whose meaning 
was unknown to the operator. Blinded analysis was achieved by using stock solutions 
prepared by a second operator, who did not participate in the heart perfusion or data analysis. 
The protocol of studies involved a randomized design with a time-matched control group, and 
blinded experimentation, data collation and analysis. For the assessment of the vehicle control 
or each individual concentration of the drug, each heart was used only once. 
2.6 Drugs and materials 
Perfusion solutions were prepared fresh each day. Dofetilide and HMR-1556 were 
synthesized at Gedeon Richter Plc. and were dissolved in DMSO. DMSO, lidocaine, ascorbic 
acid, epinephrine, norepinephrine and verapamil were purchased from Sigma-Aldrich, Inc., 
St. Louis, MO, U.S.A. The components of modified Krebs–Henseleit buffer solution (NaCl, 
CaCl2, MgSO4, NaH2PO4, NaHCO3, and KCl) were purchased from Molar Chemical Ltd., 
Budapest, Hungary. Water for the preparation of perfusion solution was obtained from a 
reverse osmosis system (Milli-Q RG, Millipore Ltd., Billerca, MA, U.S.A.) fed by distilled 
water, and had a specific resistivity of >18 M. 
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2.7 Test solutions  
DMSO control solution and all final test solutions for heart perfusion contained 0.08 ml 
DMSO in 1 l of modified Krebs-Henseleit solution in the AV ablated rabbit heart study. 
All final test solutions for heart perfusion contained 0.045 mL DMSO in 1 L of 
modified Krebs–Henseleit solution. Catecholamines (epinephrine and norepinephrine) were 
dissolved in water acidified with ascorbic acid; all final test solutions for heart perfusion 
contained 0.2 ml water and 25 µmol ascorbic acid in 1 L of modified Krebs–Henseleit 
solution in the second set of experiments in the reduced repolarization reserve rabbit heart 
study. 
2.8 Statistics 
Continuous data were expressed as mean ± standard error of the mean (S.E.M.). All 
data from independent samples, except arrhythmia incidences, were compared with Kruskal-
Wallis tests. The incidences of arrhythmias were compared by using Fisher’s exact 
probability test with the Bonferoni correction, i.e. the P values of Fisher’s exact probability 
test were multiplied by the number of comparisons between the groups to allow multiple 
comparisons 63. P<0.05 was taken as indicative of a statistically significant difference between 
values. 
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3 RESULTS 
3.1 The in vitro, isolated, AV ablated rabbit heart model 
3.1.1 The impact of AV node ablation on heart rate, QT intervals and on ECG absolute 
variability 
Mechanical AV block significantly decreased the ventricular heart rate in all groups 
(Figure 3). 
 
Figure 3. The heart rate before and after AV block in the Dofetlide, Lidocaine and Verapamil groups. 
 
Although, heart decreasing effect of AV node ablation did not lead to a regular and 
slower, spontaneous ventricular rhythm in the majority of isolated hearts, but caused a chaotic 
and irregular spontaneous ventricular rhythm (Figure 4). 
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Figue 4. Poincare´ plot of before and after AV block showing the relationship of successive QT and RR intervals to each 
other 
 
The average QT interval also lengthened significantly due to the increased RR intervals. 
As AV node ablation triggered chaotic heart rhythm, the measurement of ECG variability 
parameters was only possible during arrhythmias in many experiments. To differentiate from 
published beat-to-beat variability parameters derived during arrhythmia-free rhythm (sinus 
beat-to-beat variability parameters), we coined the term absolute to describe the beat-to-beat 
variability parameters derived irrespective of rhythm. The measured absolute QT and RR 
variability data also significantly increased and sensitize the hearts for the genesis of 
arrhythmias in the presence of proarrhythmic drugs (LTV: 6.1±0.6 ms to 9.8±0.9 ms; STV: 
5.7±0.7 ms to 9.9±1.0 ms, before AV block and after AV block, respectively) (Figure 4). 
3.1.2 The RR and the QTc intervals 
Pretreatment period 
After the exclusion of all hearts that experienced asystole longer than 20 s from the 
experiments (see exclusion criteria in 2.3.4) the mean RR interval and the mean QTc interval 
(Figure 5) did not significantly differ between the lidocaine, verapamil and the control groups 
before dofetilide perfusion. 
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Figure 5. The heart rate-corrected QT (QTc) intervals (A) and the RR intervals (B) during the pretreatment and the treatment 
periods in AV-ablated isolated rabbit hearts 
 
Treatment period 
When dofetilide was added to the perfusate verapamil further increased the dofetilide-
induced QTc prolongation leading to significant QTc lengthening. However, lidocaine did not 
affect the mean QTc interval significantly when compared with that of the DOF group 
(Figure 5). 
Verapamil on top of dofetilide perfusion significantly increased the mean RR interval 
i.e. decreased the ventricular heart rate as compared with that of the DOF group (Figure 5). 
3.1.3 The absolute variability of the RR and QT intervals 
The absolute variability parameters tended to increase of all groups in the treatment 
period, however, any of the QT or RR variability parameters did not significantly differ 
between the lidocaine, verapamil and the control groups before dofetilide perfusion neither 
during ‘Pretreatment period’ nor during treatment period (Figure 6). 
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Figure 6. The short-term variability (STV) and the long-term variability (LTV) of the QT and RR interval during the 
pretreatment and the treatment periods in AV-ablated isolated rabbit hearts 
3.1.4 TdP incidences 
In the experiments, dofetilide provoked TdP in the majority of the hearts (88%). 
Lidocaine significantly decreased the incidence of dofetilide-induced TdP (13%), while 
verapamil completely prevented the development of this arrhythmia (0%). Thus, both 
lidocaine and verapamil could significantly decrease the incidence of TdP in this model. 
3.1.5 Coronary flow 
The group mean baseline coronary flows 1 min before the ‘pretreatment’ period ranged 
from 7.9±0.5 to 10.4±0.5 ml min-1 g-1 (no significant difference between the groups). 
Perfusion with verapamil significantly increased the coronary flow as compared with the DOF 
group (the maximum coronary flow values were 13.3±1.3 and 6.7±0.2 ml min-1 g-1 in the 
VER+DOF and the DOF group, respectively). Lidocaine did not influence the coronary flow 
as compared with the DOF group (Figure 7). 
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Figure 7. The coronary flow during the pretreatment and the treatment periods in AV-ablated isolated rabbit hearts 
3.2 The in vitro, isolated, reduced repolarization reserve rabbit heart model 
3.2.1 QTc interval and heart rate in sinus rhythm 
First set of experiments  
QTc did not differ between the groups in the pretreatment period (data not shown). In 
the treatment period, administration of dofetilide for 10 min significantly prolonged the QTc 
interval, however QTc did not differentiate between the ‘Dof 15’ and the ‘HMR + Dof 15’ 
groups (Figure 8). Occurrence of dofetilide-induced arrhythmias did not allow measurement 
of the QTc interval after 10 min of dofetilide perfusion. There was no significant difference in 
the heart rate between the groups during the whole experiment (Figure 9). 
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Figure 8. The QTc intervals 10 min after the start of the dofetilide (or its vehicle) perfusion in the first set of experiments. 
*P<0.05 vs. ‘Control A’ group. For further details see Table 3. 
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Figure 9. The heart rate in the first set of experiments. HMR-1556 (or its vehicle) perfusion commenced at 0 min 
(pretreatment period). Dofetilide (or its vehicle) perfusion (treatment period) began at 30 min. For further details see Table 3. 
 
Second set of experiments 
QTc did not differ between the groups at baseline and in the pretreatment period, before 
dofetilide perfusion (data not shown). In the treatment period, administration of dofetilide for 
10 min significantly widened the QTc interval, however QTc did not differentiate between the 
‘Cat + Dof 50’ and the ‘Cat + HMR + Dof 50’ groups (Figure 10); dofetilide-induced 
arrhythmias prevented further measurements of the biomarker at the subsequent time points. 
Although catecholamines tended to increase heart rate, and HMR 1556 tended to reduce heart 
rate, there was no significant difference in the heart rate between the groups during the whole 
experiment (Figure 11). 
 
Figure 10. The QTc intervals 10 min after the start of the dofetilide (or its vehicle) perfusion in the second set of 
experiments. *P<0.05 vs. ‘Control B’ group; #P<0.05 vs. ’Cat control’ group. For further details see Table 4. 
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Figure 11. The heart rate in the second set of experiments. HMR-1556 (or its vehicle) and catecholamine perfusion 
commenced at 0 min (pretreatment period). Dofetilide (or its vehicle) perfusion (treatment period) began at 30 min. For 
further details see Table 4. 
3.2.2 Arrhythmia incidences and onset time of arrhythmias 
First set of experiments 
Hearts were in sinus rhythm during the ‘pretreatment’ period; HMR-1556 (without 
dofetilide) did not evoke arrhythmias. Dofetilide tended to increase arrhythmia incidences in 
the ‘Dof 15’, and ‘HMR + Dof 15’ groups in the ‘treatment’ period, but there were no 
significant differences in the arrhythmia incidences among the groups (data not shown). 
Dofetilide induced TdP in one heart (13%) in the ‘Dof 15’ group; the drug did not evoke 
ventricular fibrillation. There were no significant differences in the onset times of arrhythmias 
between the groups (data not shown). 
Second set of experiments 
As expected, catecholamines increased arrhythmic activity. In the pretreatment period, 
catecholamine perfusion evoked mostly VPBs, the incidences of other types of arrhythmias 
(bigeminy, salvo, VT) were low. HMR-1556 on top of catecholamines did not increase the 
incidence of any arrhythmia; there were no significant differences in the incidences of 
arrhythmias between the groups (data not shown). TdP and VF did not occur in this period. 
In the treatment period, addition of dofetilide on top of HMR-1556 and 
catecholamines increased the incidence of bigeminy, salvo, VT and VF, but the effect was not 
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significant as compared with control (Table 5). TdP occurred in one heart in both dofetilide-
perfused groups. Co-perfusion of dofetilide, HMR-1556 and catecholamines significantly 
increased the incidence of conduction blocks as an indirect sign of markedly prolonged 
repolarization (Table 5). There were no significant differences in the onset times of 
arrhythmias between the groups (data not shown). 
Incidences of arrhythmias (%) 
Group VPB BG  Salvo VT Block TdP VF 
Control B 13 13 13 0 0 0 0 
Cat control 88# 50 63 25 0 0 0 
Cat+Dof 50 75# 63 63 38 50 13 25 
Cat+HMR+Dof 50 88# 75 75 63 75*# 13 38 
 
Table 5. Percent incidences of arrhythmias during the treatment period in the second set of experiments. VPB: ventricular 
premature beat; BG: bigeminy; VT: ventricular tachycardia different from torsades de pointes; Block: conduction block of 
any kind; TdP: torsades de pointes; VF: ventricular fibrillation. *P<0.05 vs. ‘Cat control’ group; #P<0.05 vs. ‘Control B’ 
group. For further details see Table 2. 
3.2.3 Temporal inhomogeneity of the repolarization and the cycle length 
First set of experiments 
The short-term variability (STV) and long-term variability (LTV) parameters of the RR 
and QT intervals were determined in sinus rhythm (sinus variability parameters). The sinus 
STV QT and the sinus LTV QT parameters did not differ between the groups at baseline and 
during the pretreatment period (data not shown). In the treatment period, dofetilide perfusion 
for 5 min increased the sinus STV QT and the sinus LTV QT values. Importantly, both sinus 
STV QT and sinus LTV QT increased significantly in the ‘HMR + Dof 15’ group as 
compared with the values in the ‘Dof 15’ and the ‘Control A’ groups (Figure 12). The sinus 
variability parameters could not be determined at subsequent time points due to frequent 
occurrence of dofetilide-induced arrhythmias. There was no significant difference in any of 
the variability parameters of the RR interval at any time points between the groups (data not 
shown). 
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Figure 12. The short-term variability (STV) and the long-term variability (LTV) of the QT interval 5 min after the start of the 
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group. For further details Table 3. 
Second set of experiments 
The short-term variability and long-term variability of the RR and QT intervals were 
determined in sinus rhythm (sinus variability parameters) and also irrespective of the rhythm 
(absolute variability parameters). 
The sinus variability parameters of the ECG intervals 
The sinus variability parameters of the QT and RR intervals did not differ significantly 
between the groups at any predetermined time points (Figures 13 and 14). Neither 
catecholamines nor HMR-1556 influenced the sinus variability parameters during the 
pretreatment period (data not shown). Dofetilide co-administered with HMR-1556 for 5 min 
increased the sinus STV QT and LTV QT in the ‘Cat + HMR + Dof 50’ group as compared 
with the values of the ‘Cat + Dof 50’ and the control groups. However, the effect was not 
significant, most probably because the parameter could be determined in only 5 hearts in the 
‘Cat + HMR + Dof 50’ group due to frequent occurrence of dofetilide-induced arrhythmias 
(Figure 13). These arrhythmias did not allow measurement of the sinus variability parameters 
at subsequent time points. 
The absolute beat-to-beat variability of the ECG intervals 
Unlike sinus variability parameters, absolute variability parameters could be 
determined in all hearts, as measurement of the absolute variability parameters are not 
restricted to sinus rhythm. None of the absolute variability parameters of the RR and QT 
intervals differed between the groups at baseline and during the pretreatment period (data not 
shown). In the treatment period, co-perfusion of dofetilide with HMR-1556 for 5 min 
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increased the absolute variability parameters of the QT and RR intervals (Figures 13 and 14). 
Importantly, the absolute STV QT and the absolute LTV QT parameters differentiated 
between the ‘Cat + Dof 50’ and ‘Cat + HMR + Dof 50’ groups; that is the absolute variability 
parameters of the QT interval were significantly increased in the ‘Cat + HMR + Dof 50’ 
group as compared with the values in the ‘Cat + Dof 50’ group (Figure 13). 
 
Figure 13. The sinus and absolute short-term variability (STV) and long-term variability (LTV) parameters of the QT 
interval in the ‘Treatment’ period, 5 min after the start of the dofetilide (or its vehicle) perfusion in the second set of 
experiments. *P<0.05 vs. ‘Control B’ group; #P<0.05 vs. ‘Cat control’ group; †P<0.05 vs. ‘Cat + Dof 50’ group. For further 
details Table 4. 
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Figure 14. The sinus and absolute short-term variability (STV) and long-term variability (LTV) parameters of the RR 
interval in the ‘Treatment’ period, 5 min after the start of the dofetilide (or its vehicle) perfusion in the second set of 
experiments. *P<0.05 vs. ‘Control B’ group; #P<0.05 vs. ‘Cat control’ group; †P<0.05 vs. ‘Cat + Dof 50’ group. For further 
details Table 4. 
3.2.4 Coronary flow 
The mean baseline coronary flows ranged from 4.1±0.3 to 7.3±0.5 ml min-1 g-1.in the 
first set of experiments and from 4.2±0.3 to 7.4±0.7 ml min-1 g-1 in the second set of 
experiments. There was a small time-dependent fall in the coronary flow values during the 
experiments in all groups.  
In the first set of experiments there was no significant difference in the coronary flow 
between the groups. In the second set of experiments, catecholamine perfusion increased the 
flow slightly but there was no significant difference in the coronary flow between the groups 
(data not shown). 
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4 Discussion 
AV block led to a chaotic idioventricular rhythm under drug-free conditions which was 
accompanied by an elevated beat-to-beat variability of the RR and QT intervals. The 
inhibition of the Na+ channels by lidocaine as well as the block of the L-type Ca2+ channels by 
verapamil significantly antagonized the genesis of dofetilide-induced Torsades de Pointes. 
However, verapamil further increased the dofetilide-induced QTc prolongation and neither 
verapamil nor lidocaine reduced the dofetilide-induced increase in the beat-to-beat variability 
of the QT interval. Thus, neither QTc prolongation nor an increase in the beat-to-beat 
variability of the QT interval is a sufficient prerequisite of TdP genesis in rabbit hearts. 
QTc failed to predict the known increased risk of TdP in the setting of reduced 
repolarization reserve. However, a significant elevation in the sinus beat-to-beat variability 
values of the QT interval (sinus STV QT and LTV QT) indicated the increased probability of 
proarrhythmia, when drug-induced arrhythmias were infrequent during administration of a 
low concentration of dofetilide. In contrast, when catecholamines and an elevated 
concentration of dofetilide was applied, sinus beat-to-beat variability parameters of the QT 
interval could not forecast an increased hazard to proarrhythmia occurrence, since frequent 
drug-induced arrhythmias precluded measurement of the beat-to-beat variability parameters in 
sinus rhythm. However, increased absolute beat-to-beat variability parameters of the QT 
interval (absolute STV QT and LTV QT), which are determined irrespective of the rhythm 
even during arrhythmias, were indicatives of the increased risk of TdP in the setting of 
reduced repolarization reserve even when frequent arrhythmias compromised the 
measurement of the sinus STV QT and LTV QT. 
4.1 The in vitro, isolated, AV ablated rabbit heart model 
4.1.1 AV block induced a chaotic rhythm and an electrical instability 
In our study, acute AV ablation was performed in order to decrease the ventricular heart 
rate since bradycardia has been reported to improve the proarrhythmic activity of IKr 
inhibitors in isolated rabbit hearts64. However, AV block did not lead to regular bradycardic 
escape rhythm, but a chaotic idioventricular rhythm in almost all hearts under drug-free 
conditions. This chaotic idioventricular rhythm is characterized by an elevated beat-to-beat 
variability of the RR and QT intervals. Since these beat-to-beat variability parameters were 
measured under dysrhythmia (other rhythm than sinus rhythm) these parameters were 
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described as absolute variability parameters. Interestingly, similar electrical instability was 
reported in isolated mouse hearts after AV ablation, and the level of instability (i.e. the 
incidence of baseline arrhythmias after AV block) inversely correlated with the K+ 
concentration of the perfusion solution65. Thus, baseline electrical instability in the AV-
blocked rabbit hearts perfused with 3 mM K+ in the present study might contribute to the high 
sensitivity of these hearts to the proarrhythmic activity of dofetilide. 
4.1.2 The applied repolarization related biomarkers did not correlated with the incidence of 
Torsades de Pointes 
Large amount of experimental and clinical data suggest that QT prolongation alone is 
an unreliable predictor of drug-induced TdP34. In our study, to get the best QT correction 
formula matching the applied AV ablation circumstances, all QTc intervals in this study were 
corrected according to the QTc-AV (see Methods). Interestingly, verapamil exaggerated the 
dofetilide-induced QTc prolongation while it prevented the formation of TdP. Likewise, 
lidocaine could decrease significantly the incidence of TdP, but did so without affecting the 
QTc interval. These results corroborate earlier reports showing that QT prolongation did not 
correlate to the proarrhythmic liability of repolarization-prolonging drugs in isolated, AV-
ablated rabbit hearts66, 67. 
Temporal dispersion is characterized as an important mechanism of the maintenance of 
comlex proarrhythmias, e.g. Torsades de Pointes7. The temporal dispersion of repolarization 
defined as the beat-to-beat variability of the monophasic action potential duration has been 
shown to predict the proarrhythmic activity of repolarization-prolonging drugs in isolated 
rabbit hearts15 and in chronic AV-blocked dogs in vivo16. In accordance with this, Lengyel et 
al. found that the beat-to-beat variability of the QT interval predicted the occurrence of drug-
induced TdP in anaesthetized rabbits68. In contrast, the beat-to-beat variability of the QT 
interval failed to predict repolarization-prolonging-drug-induced TdP in two recent 
investigations with adrenergically stimulated, anaesthetized rabbits27, 69. Thus, the predictive 
power of an increase in the beat-to-beat variability of the QT interval is still debated. In our 
AV ablated isolated heart study, 100 nM dofetilide perfusion increased each QT variability 
parameter, and the drug induced TdP incidence reproducibly in nearly all hearts. On the other 
hand, neither verapamil nor lidocaine decreased any of the QT variability parameters, 
nevertheless, they successfully prevent the development of TdP. Thus, according to our 
results, the predictive value of an increase in beat-to-beat variability of the QT interval in 
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isolated, AV ablated, non-paced rabbit hearts is questionable. Further investigation is needed 
to clarify whether it is because an increase in the beat-to-beat variability of the action 
potential is not a contributor to TdP or rather it is because an increase in the beat-to-beat 
variability of the QT interval is only one out of several contributing factors needed to be 
present at the same time to allow generation of TdP in the model. 
4.1.3 The antitorsadogenic effect of verapamil and lidocaine 
The ICaL channel blocker verapamil significantly prolonged the QT interval in the 
presence of dofetilde and prevented the development of TdP. Verapamil has never been 
reported to cause TdP and indeed has been proposed as a therapy for long QT–related 
arrhythmias, so verapamil is considered as a relatively safe antiarrhythmic drug. However, 
verapamil can inhibit IKr in the same concentration range as quinidine and amiodarone70. This 
may explain why the drug prolonged further the QT interval in our study, when the 
repolarization reserve was very small as a result of dofetilide perfusion. Verapamil also 
decreased the heart rate (prolonged the mean RR interval), i.e. reduced the number of 
idioventricular beats mostly when it was co-perfused with dofetilide. Therefore, this effect of 
verapamil might reduce the number of trigger beats for the initiation of TdP. Since lidocaine 
tended to have the same effect on the ventricular rate, this may also explain its antiarrhythmic 
effect in our study. Shimizu et al. reported that verapamil suppressed spontaneous or 
epinephrine-induced EADs and TdP in patients with congenital LQTS71. Milberg et al. found, 
that the same concentration of verapamil we used (750 nM) prevented TdP via the reduction 
of EAD and ventricular transmural dispersion of repolarization in an isolated rabbit heart 
model of the acquired LQT3 syndrome49. Likewise, lidocaine suppressed the IKr blocker 
almokalant-induced dispersion of repolarization and the development of EADs in rabbit 
Purkinje fibres in vitro72. Thus, the antiarrhythmic effect of verapamil and lidocaine in our 
experiments may also be related their direct effect on the development of EAD and/or 
dispersion of the repolarization. 
4.2 The in vitro, isolated, reduced repolarization reserve rabbit heart model 
4.2.1 Decreased repolarization reserve augments risk of proarrhythmia, and limits the use 
of biomarkers 
Based on the theory of repolarization reserve, the fine-tuned function of repolarization 
currents may compensate the lack of a repolarizing current35, e.g. IKs may compensate the 
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decreased function of IKr. However, a multiple hit on repolarization might lead to an excessive 
APD prolongation and may render the cardiac muscle more susceptible to proarrhythmia25, 73. 
Reduction of repolarization reserve increased the incidence of dofetilide-induced TdP in 
dogs and rabbits in vivo25. Also, it was documented that the increased beta-adrenergic tone 
increased the effect of the IKs inhibitor HMR-1556 on refractoriness observed at rapid rates in 
canines in vivo56. Interestingly, neither increased concentration of dofetilide nor boosted 
HMR-1556-induced IKs inhibition due to catecholamine administration could initiate 
significant amount of dofetilide-induced TdP in the present investigation in isolated rabbit 
hearts, which highlights the importance of the surrogate biomarkers of TdP in preclinical 
drug-safety investigations. The exact reason why a low incidence of TdP was observed in the 
present investigation is not examined. The concomitant IKs and IKr block significantly 
increased the incidence of conduction blocks, which indirectly proves that the repolarization 
process was sufficiently attenuated in the present experiments50. The incidence of TdP would 
have been increased with the application of higher concentrations of dofetilde and HMR-1556 
(unpublished results from our laboratory), however, this was not the primary aim of this 
study. The combined IKs and IKr blockade did increase the incidence of less complex 
arrhythmias, and thus, prevented the use of TdP biomarkers that are based on ECG interval 
measurement restricted to sinus rhythm. However, the occurrence of arrhythmias provided 
scope for testing the predictive power of the novel TdP biomarkers, the absolute variability 
parameters28 that are not restricted to sinus rhythm. 
4.2.2 QTc failed to predict increased proarrhythmia risk in reduced repolarization reserve 
The QT and heart rate corrected QT (QTc) interval prolongation is the solely predictor 
of TdP that is unequivocally received by the authorities19, 20, although, their sensitivity and 
specificity has been strongly questioned8, 21, 22, 27-29. 
In the present study the IKr blocker dofetilide in a concentration of 15 and 50 nM caused 
a significant QTc interval prolongation as compared with the control groups. HMR did not 
lengthen QTc interval. This supports the finding of recent studies where IKs did not prolong 
QTc interval in isolated rabbit hearts39 and did not lengthen the APD in Langendorf-perfused 
rabbit hearts and in cardiac papillary muscles39, 74 reinforcing the statement that IKs may have 
little role in normal action potential repolarization and it probably plays a vital role when 
cardiac APD is abnormally lengthened by other means73. Dofetilide alone and co-perfused 
with the IKs blocker HMR-1556 caused an equivalent degree of QTc prolongation, thus the 
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extent of the QTc prolongation did not differ between the presence and absence of the IKs 
inhibition. Similarly, Lengyel et al. found that the concomitant inhibition of IKs and IKr with 
dofetilide and HMR-1556 did not prolong the QTc interval significantly as compared with 
that achieved by either the IKr or IKs inhibition in anaesthetized rabbits and dogs in vivo25. 
These results emphasize that QTc interval is not a suitable biomarker to identify increased 
TdP liability in case of reduced repolarization reserve. 
4.2.3 Sinus beat-to-beat variability of the repolarization is a better predictor of TdP in 
reduced repolarization reserve, but arrhythmic activity limits its use 
It has been suggested that temporal dispersion of repolarization could predict 
proarrhythmic events75-77. It was found in the chronic AV node blocked dog model that a 
downregulation of several potassium currents, most notably the IKs channel, occurs due to the 
electrical remodeling78. Additional pharmacological block of IKr did not prolong significantly 
the QTc interval, but increased the beat-to-beat variability of the repolarization (STV QT), 
when it was measured in arrhythmia-free, regular rhythm16. Lengyel et al. measured STV QT 
in sinus rhythm in rabbits in vivo, and directly demonstrated that TdP evoked by combined 
pharmacological block of IKr and IKs can be better predicted by increased STV QT than by 
QTc changes alone25. Carlsson et al. reported that dofetilide increased STV QT in sinus 
rhythm prior to the occurrence of ventricular premature beats and TdP in methoxamine-
sensitized, -chloralose-anaesthetized rabbits26. However, sinus STV QT did not predict TdP 
in other studies utilizing a similar, anaesthetized rabbit model27-30. 
In the first set of experiments in the present investigation the measurement of the beat-
to-beat variability of the QT intervals was possible in sinus rhythm as the arrhythmic activity 
was low during concomitant pharmacological inhibition of IKs and IKr in isolated rabbit hearts. 
In the group perfused with dofetilide together with HMR-1556 the beat-to-beat variability 
parameters of QT interval were significantly increased as compared with those in the control 
group, and more importantly, compared with those in the group perfused only with dofetilide. 
Accordingly, STV and LTV QT could differentiate the combined ion-channel block from the 
solely IKr block identifying the increased TdP liability during decreased repolarization 
reserve. 
However, in the second set of experiments, catecholamines and elevated concentration 
of dofetilide increased the arrhythmic activity, which precluded the measurement of the sinus 
beat-to-beat variability parameters of the QT intervals, thus these parameters failed to indicate 
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the increased proarrhythmic liability of the drugs during reduced repolarization reserve. These 
results show that sinus beat-to-beat variability parameters of the repolarization (sinus STV QT 
and LTV QT) are better predictors of TdP than QTc in reduced repolarization reserve, 
although the application of these parameters is limited when arrhythmia occurs. 
4.2.4 Absolute beat-to-beat variability of the repolarization is the best proarrhythmia 
predictor in reduced repolarization reserve 
In the presence of reduced repolarization reserve ectopic beats can render the APD 
unstable for many beats15 and thus produce large beat-to-beat irregularity79. However, 
increased variability of repolarization may remain latent until the heart is disturbed by an 
ectopic beat80. In a previous in vivo study, most TdP events were preceded by less complex 
arrhythmias (e.g. VPBs, salvos, bigeminy, etc.) in an anesthetized rabbit proarrhythmia 
model28. Similar non-complex arrhythmias occurred frequently in the second set of 
experiments in the present in vitro investigation, when hearts were sensitized to arrhythmia 
development by the co-perfusion of catecholamines and an elevated concentration of 
dofetilide. Since TdP rarely occurs spontaneously without preceding arrhythmias, however 
the number of arrhythmic beats was not a precise predictor of drug-induced TdP28, new TdP 
biomarkers that can be measured irrespective of the rhythm even during arrhythmias are 
needed. The sinus beat-to-beat variability of the repolarization can predict TdP development, 
but its predictive power is not consistent especially when frequent arrhythmias preclude its 
measurement. However, the newly developed absolute beat-to-beat variability parameters of 
the ECG intervals seem to be more reliable surrogate biomarkers of TdP28. Indeed, in the 
present study, where the sinus beat-to-beat variability was not predictive in the second set of 
experiments, the absolute beat-to-beat variability parameters of the repolarization still 
indicated the increased proarrhythmic liability of dofetilide in the setting of decreased 
repolarization reserve. 
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 QTc sinus 
variability 
absolute 
variability 
simple 
arrhythmia 
complex 
arrhythmia 
AV ablation study      
DOF (vs. control
#
 not evaluable ( vs. control# not evaluable ( TdP vs. 
control# 
LID+DOF ( vs. DOF not evaluable - not evaluable )TdP 
VER+DOF ( vs. DOF* not evaluable ( vs. DOF not evaluable )TdP 
Repol. reserve study 
1. series 
     
DOF15 ( vs. control A* ( vs. control A* not evaluable ( vs. control A ( vs. control A 
HMR+DOF15  ( vs. control A* ( vs. control A/DOF15* 
not evaluable ( vs. control A - 
Repol. reserve study 
2. series 
     
CATcontrol - - ( vs. control B ( vs.control B* ( vs. control B 
CAT+DOF50 ( vs. control B/CAT control* 
- ( vs. control B ( vs.control B* ( vs. control B 
CAT+DOF50+HMR ( vs. control B/CAT control* 
( vs. each 
group 
( vs. each 
group* 
( vs.control B* ( vs. control B 
 
Table 6. Summarizing table of the assessed proarrhythmia biomarkers of the two studies. See the difference between 
decreased repolarization reserve group vs. simple IKr inhibited group, highlighted with red; not evaluable: the parameter 
cannot have been measured/evaluated # p<0.05 vs. control group in first series of experiments in AV ablation study (not 
detailed); *p<0.05, significant change 
4.2.5 The efficacy of the applied proarrhythmia biomarkers in TdP forecast 
Summarizing our assessment of TdP predictors in the two similar Langendorff TdP 
model, we can conclude that beat-to-beat variability parameters could reliably forecast the 
higher chance of TdP development (Table 6). The applied absolute variability parameter 
allow the analysis of ECG segments during arrhythmia, therefore, the beat-to-beat ECG 
analysis is not only restricted to sinus or stable, regular rhythm. The beat-to-beat variability 
parameters tended to be more sensitive than QTc, or simple arrhythmia analysis alone in the 
TdP prediction. However, the specificity of variability parameters is still merit further 
assessment. 
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5 Conclusion 
AV ablation resulted in a chaotic idioventricular rhythm, which might make the hearts 
more sensitive to the proarrhythmic activity of dofetilide in the applied isolated rabbit heart 
model. In our AV ablated model, the inhibition of the INa and ICaL currents successfully 
antagonized the genesis of this arrhythmia. Neither QTc prolongation nor an increase in the 
beat-to-beat variability of the QT interval is a sufficient prerequisite of TdP genesis in this 
model. 
QTc prolongation did not identify the higher proarrhythmic risk of dofetilide in the 
setting of reduced repolarization reserve in isolated rabbit hearts. In contrast, the sinus beat-
to-beat variability of QT interval as a TdP biomarker indicating temporal dispersion of 
repolarization was a sensitive biomarker of proarrhythmia in the setting of decreased 
repolarization reserve. However, when measurement of the sinus variability parameters was 
hindered by arrhythmias caused by addition of catecholamines and an increased concentration 
of dofetilide, only absolute beat-to-beat variability parameters of the repolarization could 
reveal the higher TdP liability in the setting of reduced repolarization reserve. This confirms 
that the absolute beat-to-beat variability parameters of the repolarization (absolute STV QT 
and LTV QT) are very sensitive and useful biomarkers of proarrhythmia. 
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